FIELD: biotechnology.
SUBSTANCE: invention relates to a specific binding molecule having the property of binding to the (GLSPTVWLSV and/or GLSPTVWLSA)-HLA-A*02 complex, as well as to a hybrid molecule and a composition containing it. Also disclosed is a nucleic acid coding said molecule or hybrid molecule, as well as a vector, a cell containing it.
EFFECT: invention is effective for treating chronic HBV infection in a subject.
27 cl, 9 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
| BISPECIFIC MOLECULES, IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR | 2014 |
|
RU2721707C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
